Clinical trial registry record

Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD)

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 12, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02395757
Last registry update
September 12, 2025
Status
Completed
Phase
Phase not reported
Sponsor
Hospices Civils de Lyon
Enrollment
182
Countries
France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
NA · SINGLE GROUP · DIAGNOSTIC · NONE
Evidence population
Human clinical study registration
Participants
182
Population
ALL · 50 Years
Duration
2015-09-01 to 2020-01-08
Intervention
MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)
Comparator
Not reported
Outcomes measured
The sensitivity of the microperimetric parameter(s) and combination(s) of parameters according to patient status at fin…; The specificity of the microperimetric parameter or combination of parameters with the highest level of sensitivity — 2…; The positive predictive value of the microperimetric parameter or combination of parameters with the highest level of s…; The negative predictive value of the microperimetric parameter or combination of parameters with the highest level of s…; The sensitivity of the microperimetric parameters associated with the parameters from other ophthalmological examinatio…; The specificity of the microperimetric parameters associated with the parameters from other ophthalmological examinatio…; The sensitivity of the microperimetric parameters or combinations of parameters for the sub-group of eyes presenting re…; The specificity of the microperimetric parameters or combinations of parameters for the sub-group of eyes presenting re…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON